1367 completed, 549 recruiting, 525 active not recruiting, 442 terminated. 1426 Phase 2, 826 Phase 1, 562 Not applicable, 141 Phase 3, 75 Early Phase 1.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 2 | 1426 | Completed 582, Terminated 244, Active not recruiting 234, Recruiting 215, Withdrawn 111, Not yet recruiting 23, Suspended 9, Unknown 8 |
| Phase 1 | 826 | Completed 357, Terminated 138, Recruiting 132, Active not recruiting 89, Withdrawn 78, Not yet recruiting 17, Unknown 8, Suspended 7 |
| Not applicable | 562 | Completed 213, Active not recruiting 134, Recruiting 100, Terminated 44, Withdrawn 28, Not yet recruiting 25, Unknown 12, Enrolling by invitation 3, Suspended 3 |
| Phase 3 | 141 | Completed 67, Active not recruiting 25, Terminated 25, Recruiting 14, Withdrawn 6, Not yet recruiting 2, Suspended 1, Unknown 1 |
| Early Phase 1 | 75 | Completed 29, Active not recruiting 21, Terminated 9, Recruiting 8, Withdrawn 7, Suspended 1 |
| Phase 4 | 35 | Completed 16, Terminated 9, Recruiting 5, Active not recruiting 4, Enrolling by invitation 1 |
Follow M.D. Anderson Cancer Center: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 58 | 2027-12-01 | 2026-08-25 |
Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration
RayAblation - Liver Tumors | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2027-04-01 | 2026-10-16 |
Long-Term Quality Of Life And Symptom Assessment Among Recurrence-Free Patients Who Underwent Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Questionnaire and Physical Exam - Long Term, Quality of Life | | Not yet recruiting | M.D. Anderson Cancer Center | 300 | 2027-03-22 | 2026-10-13 |
Food Is Medicine In Survivorship (Foodiis-AYA): Examining The Feasibility And Acceptability Of A Remotely-Delivered Meal Kit And Culinary Medicine Program For Survivors Of Adolescent/Young Adult (AYA) Cancer
Meal Preps, Questionnaire - Survivorship, Meal Kit | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 15 | 2027-03-16 | 2026-10-13 |
Prospective Study To Assess The Outcomes Of Nitrous Oxide Cryoablation For Treatment Of Duodenal Adenomas In Patients With Hereditary Conditions Such As FAP, HNPCC
Esophagogastroduodenoscopy - Prospective Study , Questionaires, Outcomes | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-03-03 | 2026-10-05 |
A Ph2, Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy
Colchicine, Placebo - Head and Neck Cancer | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 250 | 2027-03-01 | 2026-10-05 |
Understanding the Role of MyCareGorithm as a Visual Digital Platforms in Cancer Treatment Education and Patient Comprehension of Oncology Treatment Plans
Survey - Head and Neck Cancer, Prostate Cancer | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 94 | 2027-03-01 | 2026-10-01 |
Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors
Olaparib, Gemcitabine, Docetaxel - Germ Cell Cancer | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 36 | 2027-03-01 | 2026-10-01 |
2 Gy Total Body Irradiation As Part Of Conditioning Treatment For Patients With Acute Lymphoblastic Leukemia Undergoing CAR T Cell Therapy
CAR T cell therapy - Acute Lymphoblastic Leukemia | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-03-01 | 2026-10-05 |
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Larotrectinib, Pembrolizumab - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 22 | 2027-03-01 | 2026-09-28 |
MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study
Disulfiram 250 mg, Copper Gluconate 2 mg, Radiation Therapy - Thoracic Cancer | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2027-03-01 | 2026-09-28 |
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
Prednisone, Ajovy, Manual Therapy - Cranial Nerve Injury, Oropharyngeal Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 48 | 2027-03-01 | 2026-09-21 |
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine - Hematological Malignancies | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 70 | 2027-02-28 | 2026-08-20 |
PRECISE LBCL: Precision Treatment Readiness Through Comprehensive Genomic Sequencing in 1st Line LBCL
Standard of Care (SOC) - LBCL, Comprehensive Genomic | | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-02-25 | 2026-09-21 |
Impact of Routine Electronic Patient-Reported Outcome (ePRO)Symptom Monitoring During Neoadjuvant Therapy in Patients withPancreatic Adenocarcinoma on Patient Experience and ClinicalOutcomes: A Prospective Pre-Post Implementation Study
Standard of Care - ePRO, Symptom Monitoring | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2027-02-21 | 2026-09-21 |
Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With
Crefmirlimb, PET/CT imaging - Tumor Infiltrating Lymphocyte, CD8-PET | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 6 | 2027-02-18 | 2026-09-15 |
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma
Epcoritamab, Observation - Randomized, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2027-02-12 | 2026-09-23 |
Zotatifin And EIF4A Platinum Helix Inhibition In Resistant AdvancedTNBC
Zotatifin, carboplatin - Phase IB, Zotatifin | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 24 | 2027-02-12 | 2026-09-08 |
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-02-07 | 2026-09-18 |
RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT
LX-101 - Ewing Sarcoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 120 | 2027-02-01 | 2026-08-24 |
Showing 20 of 3311. Sign in to see all of them.
Conditions studied
Leukemia (246) · Breast Neoplasms (238) · Leukemia, Myeloid, Acute (199) · Neoplasms (191) · Lung Neoplasms (171) · Lymphoma (163) · Myelodysplastic Syndromes (152) · Prostatic Neoplasms (139) · Neoplasm Metastasis (135) · Leukemia, Lymphocytic, Chronic, B-Cell (119) · Carcinoma, Non-Small-Cell Lung (117) · Melanoma (112) · Hematologic Neoplasms (102) · Colorectal Neoplasms (98) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (93)
Interventions
Surveys and Questionnaires (362) · Cyclophosphamide (182) · Rituximab (140) · fludarabine (123) · Radiotherapy (116) · fludarabine phosphate (116) · Cytarabine (104) · Dexamethasone (91) · Doxorubicin (85) · Calcium Dobesilate (82) · Bevacizumab (81) · pembrolizumab (79) · Carboplatin (78) · Filgrastim (77) · Interviews as Topic (77)
Countries
United States (3095) · Canada (31) · China (12) · Netherlands (11) · Brazil (10) · Italy (8) · Australia (6) · Denmark (5) · Mexico (5) · Spain (5) · United Kingdom (5) · Colombia (4) · France (4) · Israel (4) · Peru (4)
Top investigators
Jorge Cortes, MD (19) · Courtney DiNardo, MD (16) · David Hui, MD (16) · Elias Jabbour, MD (16) · Aung Naing, MD (15) · David S. Hong, MD (15) · Elias Jabbour (15) · Eric Jonasch, MD (15) · Farhad Ravandi-Kashani, MD (14) · Guillermo Garcia-Manero, MD (13) · Lorenzo Cohen, PHD (13) · Saroj Vadhan-Raj, MD (13) · Tapan M Kadia (13) · Eduardo Bruera, MD (12)
Results publications
PMID 35622074, PMID 28835440, PMID 30885996, PMID 41671463, PMID 22586319, PMID 23442309, PMID 23620574, PMID 29358183, PMID 32379297, PMID 39319495, PMID 27482888, PMID 29702001, PMID 31401903, PMID 33951890, PMID 36648215, PMID 37142273, PMID 38551807, PMID 30028037, PMID 31838154, PMID 31952842, PMID 31996395, PMID 33198942, PMID 33484847, PMID 33782093, PMID 34036820, PMID 34515338, PMID 34611902, PMID 34797699, PMID 35420700, PMID 35952327, PMID 36658425, PMID 36848607, PMID 36999619, PMID 37146227, PMID 38578640, PMID 39558017, PMID 40366003, PMID 40513054, PMID 41290309, PMID 12610188, PMID 12947059, PMID 13230442, PMID 13335513, PMID 14582678, PMID 15613697, PMID 15838205, PMID 16083707, PMID 16258090, PMID 16384850, PMID 16417220
NIH funding
P30CA016672 (204), P01CA021239 (8), P50CA083639 (6), U01CA070172 (6), U10CA045809 (6), P50CA091846 (5), P50CA090270 (4), P50CA098258 (4), R01CA061508 (4), U01DK108328 (4), U19CA021239 (4), P01CA148600 (3), P50CA093459 (3), P50CA100632 (3), R01CA026582 (3)